Program
Semaglutide
Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 1518 open or running | phase 4since Jul 11, 2018 | Jun 11, 2008 | Dec 13, 2026phase 1 · NCT07225816 |
| CSPC Pharmaceutical Group | 20 open or running | phase 3since Nov 30, 2023 | Nov 30, 2023 | none ahead |
| Hangzhou Jiuyuan Gene Engineering | 21 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| chengdu-brilliant-pharmaceutical-co-ltd | 11 open or running | phase 3since Mar 18, 2024 | Mar 18, 2024 | none ahead |
| Geropharm | 10 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Gila Therapeutics | 11 open or running | phase 4since Apr 17, 2026 | Apr 17, 2026 | May 2027phase 4 · NCT07728383 |
| Korea United Pharm. | 11 open or running | phase 1since Oct 28, 2026 | Oct 28, 2026 | Nov 1, 2027phase 1 · NCT07935200 |
| Qilu Pharmaceutical | 11 open or running | phase 3since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Shanghai World Leader Pharmaceutical | 11 open or running | phase 1since Jan 28, 2026 | Jan 28, 2026 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 3since Dec 13, 2024 | Dec 13, 2024 | none ahead |
| Vivani Medical | 11 open or running | phase 1since Feb 10, 2026 | Feb 10, 2026 | Dec 2026phase 1 · NCT07430059 |
Also a collaborator on its studies: celerion and avance-clinical-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 16, 2020.
- Aug 22, 2024Phase 4 study in ObesityNovo Nordisk · NCT06571383 · 500 enrolled · United States, Belgium, Canada and more
- Sep 12, 2024Phase 3 study in Weight ManagementCSPC Pharmaceutical Group · NCT06604624 · 462 enrolled · China
- Oct 7, 2024Phase 3 study in ObesityHangzhou Jiuyuan Gene Engineering · NCT06633783 · 370 planned · China
- Oct 13, 2024Phase 1 study in Healthy Volunteers Type 2 DiabetesNovo Nordisk · NCT06642584 · 90 enrolled · Canada
- Dec 13, 2024Sino Biopharmaceutical's first study: phase 3 study in ObesityNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06738979 · 408 enrolled · China
- Nov 5, 2025Phase 1 study in ObesityNovo Nordisk · NCT07225816 · 71 planned · United States
- Nov 27, 2025Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT07271251 · 267 enrolled · Japan
- Jan 28, 2026Shanghai World Leader Pharmaceutical's first study: phase 1 study in OverweightNew to Shanghai World Leader PharmaceuticalShanghai World Leader Pharmaceutical · NCT07465965 · 60 planned · United States
- Feb 10, 2026Vivani Medical's first study: phase 1 study in ObesityNew to Vivani MedicalVivani Medical · NCT07430059 · 20 planned
- Apr 17, 2026Gila Therapeutics's first study: phase 4 study in ObesityNew to Gila TherapeuticsGila Therapeutics · NCT07728383 · 40 planned · United States
- Aug 13, 2026Phase 3 study in OverweightNovo Nordisk · NCT07770841 · 450 planned · United States, Belgium, Bulgaria and more
- Sep 22, 2026Phase 1 study in ObesityNovo Nordisk · NCT07845578 · 60 planned · Austria
- Oct 21, 2026Phase 4 study in Renal Insufficiency, ChronicNovo Nordisk · NCT07900438 · 300 planned · China
- Oct 28, 2026Korea United Pharm.'s first study: phase 1 study in BioequivalenceNew to Korea United Pharm.Korea United Pharm. · NCT07935200 · 44 planned · South Korea
Ahead
- Dec 2026Primary completion: phase 1 study in ObesityVivani Medical · NCT07430059
- Dec 13, 2026Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07225816
- May 2027Primary completion: phase 4 study in ObesityGila Therapeutics · NCT07728383
- Sep 11, 2027Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07845578
TargetBeta
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
The newest 60 of 163 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07935200Bioequivalence · South Korea | 1 | Not yet recruiting | Korea United Pharm. | Nov 1, 2027 | 44 |
| NCT07900438Renal Insufficiency, Chronic · China | 4 | Recruiting | Novo Nordisk | Dec 20, 2029 | 300 |
| NCT07845578Obesity · Austria | 1 | Not yet recruiting | Novo Nordisk | Sep 11, 2027 | 60 |
| NCT07770841Overweight · United States, Belgium, Bulgaria and more | 3 | Recruiting | Novo Nordisk | Feb 22, 2028 | 450 |
| NCT07728383Obesity · United States | 4 | Recruiting | Gila Therapeutics | May 2027 | 40 |
| NCT07430059Obesity | 1 | Not yet recruiting | Vivani Medical | Dec 2026 | 20 |
| NCT07465965Overweight · United States | 1 | Recruiting | Shanghai World Leader Pharmaceutical | Aug 21, 2026 | 60 |
| NCT07271251Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Novo Nordisk | Jun 29, 2026 | 267 |
| NCT07225816Obesity · United States | 1 | Recruiting | Novo Nordisk | Dec 13, 2026 | 71 |
| NCT06738979Obesity · China | 3 | Completed | Sino Biopharmaceutical | Mar 7, 2026 | 408 |
| NCT06642584Healthy Volunteers Type 2 Diabetes · Canada | 1 | Completed | Novo Nordisk | Jul 10, 2025 | 90 |
| NCT06633783Obesity · China | 3 | Not yet recruiting | Hangzhou Jiuyuan Gene Engineering | May 30, 2026 | 370 |
| NCT06604624Weight Management · China | 3 | Completed | CSPC Pharmaceutical Group | Aug 27, 2025 | 462 |
| NCT06571383Obesity · United States, Belgium, Canada and more | 4 | Active, not recruiting | Novo Nordisk | Nov 15, 2028 | 500 |
| NCT06497049Pharmacokinetics · Russian Federation | 1 | Completed | Geropharm | May 5, 2024 | 120 |
| NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more | 2 | Completed | Novo Nordisk | Nov 21, 2025 | 270 |
| NCT06339086Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | chengdu-brilliant-pharmaceutical-co-ltd | Aug 30, 2025 | 478 |
| NCT06267092Overweight · Germany | 1 | Completed | Novo Nordisk | Apr 7, 2025 | 164 |
| NCT06161844Diabetes Mellitus, Type 2 · China | 3 | Completed | CSPC Pharmaceutical Group | May 14, 2025 | 506 |
| NCT06097390Healthy Participants · Canada | 1 | Completed | Novo Nordisk | Feb 22, 2024 | 121 |
| NCT06083675Diabetes Mellitus, Type 2 · United States, Brazil, Bulgaria and more | 3 | Withdrawn | Novo Nordisk | Jan 24, 2025 | 0 |
| NCT06041217Overweight · China, Taiwan | 3 | Completed | Novo Nordisk | Apr 2, 2025 | 242 |
| NCT05996874Healthy Participants · Germany | 1 | Completed | Novo Nordisk | Apr 18, 2024 | 121 |
| NCT05950516Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Qilu Pharmaceutical | Nov 24, 2024 | 478 |
| NCT05891496Alzheimer Disease · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Aug 19, 2024 | 23 |
| NCT05890976Overweight · China | 3 | Completed | Novo Nordisk | Jan 16, 2025 | 200 |
| NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more | 3 | Completed | Novo Nordisk | Apr 14, 2025 | 148 |
| NCT05784402Healthy Participants · United States, Canada | 1 | Completed | Novo Nordisk | Feb 23, 2024 | 264 |
| NCT05816057Diabetes Mellitus, Type 2 · China | 3 | Completed | Hangzhou Jiuyuan Gene Engineering | Jul 25, 2023 | 476 |
| NCT05726227Obesity · United States, Austria, Belgium and more | 3 | Active, not recruiting | Novo Nordisk | Oct 15, 2025 | 212 |
| NCT05689099Diabetes Mellitus, Type 2 · United States | 1 | Completed | Novo Nordisk | May 30, 2023 | 20 |
| NCT05649137Obesity · United States, Bulgaria, Canada and more | 3 | Completed | Novo Nordisk | Oct 28, 2024 | 512 |
| NCT05646706Obesity · United States, Bulgaria, Canada and more | 3 | Completed | Novo Nordisk | Oct 30, 2024 | 1,407 |
| NCT05579249Obesity · United States | 4 | Completed | Novo Nordisk | Nov 27, 2024 | 500 |
| NCT05564117Overweight · United States, Canada, Germany and more | 3 | Completed | Novo Nordisk | Apr 18, 2024 | 307 |
| NCT05533632Diabetes Mellitus, Type 2 · Chile | 4 | Completed | Novo Nordisk | Jan 18, 2024 | 104 |
| NCT05514535Diabetes Mellitus, Type 2 · United States, Czechia, Greece and more | 3 | Completed | Novo Nordisk | Mar 5, 2025 | 573 |
| NCT05486065Diabetes Mellitus, Type 2 · United States, Greece, Hungary and more | 2 | Completed | Novo Nordisk | Oct 12, 2023 | 245 |
| NCT05478252Diabetes Mellitus, Type 2 · United States, Canada, Poland and more | 3 | Completed | Novo Nordisk | Aug 9, 2023 | 388 |
| NCT05444153Diabetes Mellitus, Type 2 | 3 | Withdrawn | Novo Nordisk | Oct 2, 2024 | 0 |
| NCT05429593Healthy Volunteers · Germany | 1 | Completed | Novo Nordisk | Mar 10, 2023 | 152 |
| NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Novo Nordisk | Mar 19, 2024 | 1,291 |
| NCT05227196Diabetes Mellitus, Type 2 · United States, Canada | 1 | Completed | Novo Nordisk | Jun 28, 2023 | 546 |
| NCT05232708Diabetes Mellitus · United Kingdom | 1 | Completed | Novo Nordisk | Aug 30, 2022 | 18 |
| NCT05132088Overweight · Japan, South Korea | 3 | Completed | Novo Nordisk | Jul 11, 2023 | 201 |
| NCT05064735Obesity · United States, Canada, Colombia and more | 3 | Completed | Novo Nordisk | Jul 24, 2023 | 407 |
| NCT05040971Obesity · Canada, Denmark, Finland and more | 3 | Completed | Novo Nordisk | Jan 6, 2023 | 207 |
| NCT05035095Obesity · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Mar 24, 2023 | 667 |
| NCT05035082Diabetes Mellitus, Type 2 · United States | 4 | Completed | Novo Nordisk | Jun 18, 2025 | 1,018 |
| NCT04998136Obesity · South Korea, Thailand | 3 | Completed | Novo Nordisk | Oct 16, 2023 | 150 |
| NCT04940078Obesity · Canada, Denmark | 1 | Completed | Novo Nordisk | Jan 19, 2022 | 40 |
| NCT04916470Diabetes Mellitus · United States, Argentina, Austria and more | 3 | Completed | Novo Nordisk | Oct 11, 2023 | 617 |
| NCT04865770Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Nov 21, 2024 | 106 |
| NCT04822181Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novo Nordisk | Apr 25, 2029 | 1,205 |
| NCT04817644Diabetes Mellitus, Type 2 · United States | 1 | Completed | Novo Nordisk | May 26, 2023 | 14 |
| NCT04788511Obesity · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Apr 18, 2023 | 529 |
| NCT04777409Early Alzheimer´s Disease · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Sep 15, 2025 | 1,840 |
| NCT04777396Alzheimer Disease · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Sep 16, 2025 | 1,840 |
| NCT04707469Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more | 3 | Completed | Novo Nordisk | Mar 7, 2023 | 1,606 |
| NCT04596631Diabetes Mellitus, Type 2 · United States, Australia, Austria and more | 3 | Completed | Novo Nordisk | Apr 29, 2025 | 132 |
How it is read
Names in the registry
- “semaglutide”, 83 entries
- “Semaglutide”, 66 entries
- “Oral semaglutide”, 11 entries
- “Semaglutide 2.4 mg”, 3 entries
- “Semaglutide J”, 3 entries
Codes read as this program: UI112, HD1916.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 94 studies
- Obesity, 42 studies
- Diabetes Mellitus, 17 studies
- Non-alcoholic Fatty Liver Disease, 4 studies
- Alzheimer Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.